This study compares the effectiveness of hepatic arterial infusion of mitomycin C with that of 5-fluorouracil in the management of carcinoma of the colon metastatic to the liver. A higher tumor response rate was obtained with 5-FU (ten of 12 patients) than with mitomycin C (six of 13 patients). The patients treated with mitomycin C had a median survival time of 9.5 months compared to 12 months for those receiving 5-FU, but this survival is not much different from that of the untreated historical controls. Femoral artery thrombosis requiring surgical thrombectomy developed in five of the 30 catheterized patients.

Adenocarcinoma↗

PubMedDate not supplied

Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine.

Forty consecutive patients with small cell bronchogenic carcinoma were treated. The first 18 patients were treated with CCNU and doxorubicin (Adriamycin) (CA). The next 22 patients were treated with CCNU, doxorubicin, procarbazine, and vincristine (CAPO). Patient characteristics were similar. The partial plus complete response rate was 55% (ten of 18 patients) in the CA group compared to 41% (nine of 22 patients) in the CAPO group. The median survival from treatment was 28 weeks in the CA group compared to 33 weeks in the CAPO group. There were no drug-related deaths among the patients receiving CA compared to two definite and three probably drug-related deaths among the patients receiving CAPO. The addition of procarbazine and vincristine to CA for the treatment of small cell bronchogenic carcinoma resulted in increased toxicity and no survival benefit.

Antineoplastic Agents↗